[BPMC] Blueprint Medicines Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 28.15 Change: 1.24 (4.61%)
Ext. hours: Change: 0 (0%)

chart BPMC

Refresh chart

Strongest Trends Summary For BPMC

BPMC is in the medium-term up 26% above S&P in 3 months. In the long-term up 212% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-550 K Cash From Investing Activities-1.28 M Cash From Operating Activities4.89 M Gross Profit
Net Profit-11.57 M Operating Profit-11.35 M Total Assets55.91 M Total Current Assets52.18 M
Total Current Liabilities14.63 M Total Debt8.65 M Total Liabilities31.19 M Total Revenue650 K
Technical Data
High 52 week102.95 Low 52 week45.57 Last close72.19 Last change-1.18%
RSI67.74 Average true range2.76 Beta1.43 Volume291.22 K
Simple moving average 20 days6.2% Simple moving average 50 days20.26% Simple moving average 200 days6.23%
Performance Data
Performance Week3.8% Performance Month34.99% Performance Quart9.79% Performance Half5.77%
Performance Year-8.68% Performance Year-to-date33.91% Volatility daily3.35% Volatility weekly7.49%
Volatility monthly15.35% Volatility yearly53.16% Relative Volume181.66% Average Volume367.58 K
New High New Low

News

2019-03-23 12:14:00 | 3 Cancer Treatment Stocks to Buy in March

2019-03-05 08:01:00 | Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference

2019-03-01 07:10:00 | Market Trends Toward New Normal in ITT, Palo Alto Networks, Enterprise Products Partners, Blueprint Medicines, Lincoln Electric, and NewMarket — Emerging Consolidated Expectations, Analyst Ratings

2019-02-26 18:12:32 | Edited Transcript of BPMC earnings conference call or presentation 26-Feb-19 1:30pm GMT

2019-02-26 13:16:16 | Blueprint Medicines Corp BPMC Q4 2018 Earnings Conference Call Transcript

2019-02-26 07:00:00 | Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-21 16:00:00 | 3 Top Healthcare Stocks to Buy in February

2019-02-19 08:00:00 | Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

2019-02-13 10:31:03 | Earnings Preview: Blueprint Medicines BPMC Q4 Earnings Expected to Decline

2019-02-08 08:04:50 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2019-02-07 16:01:00 | Blueprint Medicines to Present at Upcoming Investor Conferences in February

2019-01-29 08:05:09 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2019-01-24 09:00:00 | Three Companies Using AI and Innovation to Lead Healthcare Sector

2019-01-17 15:50:50 | Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table

2019-01-17 15:50:50 | Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table

2019-01-15 08:03:26 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2019-01-09 08:03:50 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2019-01-07 15:47:00 | Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today

2019-01-07 15:06:00 | Cancer stocks heat up after third big merger in the past month

2019-01-04 08:00:00 | Blueprint Medicines Announces _2020 Blueprint_ Global Business Strategy and Outlines Key Corporate Goals

2018-12-20 08:02:18 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-12-17 07:20:00 | Analysis: Positioning to Benefit within Quidel, Granite Construction, FireEye, Consolidated Edison, EnPro Industries, and Blueprint Medicines — Research Highlights Growth, Revenue, and Consolidated Results

2018-12-08 08:02:21 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-12-08 07:10:06 | Is Blueprint Medicines Corporation BPMC A Good Stock To Buy?

2018-12-06 08:02:32 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-12-04 12:14:07 | Is Blueprint Medicines Corporation’s NASDAQ:BPMC CEO Overpaid Relative To Its Peers?

2018-12-02 12:30:00 | Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis

2018-11-24 08:03:19 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-11-22 08:03:21 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-11-15 07:00:00 | Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy

2018-11-09 08:04:06 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-11-05 07:40:00 | Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-30 16:05:03 | Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT

2018-10-30 08:50:12 | Blueprint Medicines BPMC Reports Q3 Loss, Misses Revenue Estimates

2018-10-30 07:44:23 | Blueprint Medicines: 3Q Earnings Snapshot

2018-10-30 07:00:00 | Blueprint Medicines Reports Third Quarter 2018 Financial Results

2018-10-29 16:01:00 | Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International

2018-10-25 08:03:35 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-10-23 16:01:00 | Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018

2018-10-23 10:32:02 | Blueprint Medicines BPMC Q3 Earnings Preview: What to Look Out For

2018-10-20 08:03:20 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-10-08 08:20:00 | Report: Exploring Fundamental Drivers Behind Masonite International, Chart Industries, Blueprint Medicines, Cross Country Healthcare, HNI, and Paylocity Holding — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-08 08:03:30 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-10-06 08:50:00 | Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers

2018-10-01 08:00:00 | Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva

2018-09-26 08:00:00 | Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion

2018-09-24 08:00:00 | Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings

2018-09-20 08:04:05 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-09-18 08:04:24 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2018-09-15 08:04:14 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.